GL Pharm Tech Corp.

Equities

A204840

KR7204840003

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-22 EDT			5-day change	1st Jan Change
1,171 ^KRW	-1.35%		-3.70%	+3.08%

05-03	An undisclosed buyer acquired 3.23% stake in GL Pharm Tech Corp. from Ideal Private Equity Fund for KRW 3.97 billion.	CI
03-06	W Science Co., Ltd. completed the acquisition of 14.75% stake in GL Pharm Tech Corp. from Ideal Private Equity Fund	CI

GL Pharm Tech Corp. announced that it has received KRW 7 billion in funding from Shinhan Investment Corp., Investment Arm, Samsung Securities Co. Ltd., Investment Arm, E&INVESTMENT INC. and other investors

May 13, 2018

On May 14, 2018, GL Pharm Tech Corp. (KOSDAQ:A204840) closed the transaction.

Latest news about GL Pharm Tech Corp.

An undisclosed buyer acquired 3.23% stake in GL Pharm Tech Corp. from Ideal Private Equity Fund for KRW 3.97 billion.	05-02	CI
W Science Co., Ltd. completed the acquisition of 14.75% stake in GL Pharm Tech Corp. from Ideal Private Equity Fund	03-05	CI
GL Pharm Tech Corp. announced that it has received KRW 9.199999458 billion in funding from W Science Co., Ltd.	03-05	CI
GL Pharm Tech to Raise 9.2 Billion Won via Share Issuance; Shares Decline 7%	23-09-14	MT
GL Pharm Tech Corp. announced that it expects to receive KRW 9.199999458 billion in funding from W Science Co., Ltd.	23-09-13	CI
W Science Co., Ltd. agreed to acquire a 14.7% stake in GL Pharm Tech Corp.	23-09-13	CI
GL Pharm Tech Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-08	CI
GL Pharm Tech Corp. Auditor Raises 'Going Concern' Doubt	23-03-16	CI
GL Pharm Tech Corp. Auditor Raises 'Going Concern' Doubt	22-03-16	CI
GL Pharm Tech Corp. announced that it expects to receive KRW 8.999999634 billion in funding from Ideal Private Equity Fund	20-11-22	CI
GL Pharm Tech Corp. announced that it has received KRW 1.000000232 billion in funding from Kyperion Co., Ltd.	20-09-28	CI
GL Pharm Tech Corp. announced that it expects to receive KRW 1.000000232 billion in funding from Kyperion Co., Ltd.	20-09-20	CI
GL Pharm Tech Corp. announced that it has received KRW 1.000000534 billion in funding from Kuhnil Pharmaceutical Co., Ltd.	20-08-11	CI
GL Pharm Tech Corp. announced that it expects to receive KRW 1.000000534 billion in funding from Kuhnil Pharmaceutical Co., Ltd.	20-07-28	CI
GL Pharm Tech Corp. announced that it has received KRW 3.1 billion in funding from Unione Communications Co., Ltd.	20-05-12	CI
GL Pharm Tech Corp. announced that it expects to receive KRW 3.1 billion in funding from Unione Communications Co., Ltd. and other investors	20-05-06	CI
Crown Pharm Co., Ltd. announced that it has received KRW 1.00001 billion in funding from GL Pharm Tech Corp.	18-12-16	CI
Crown Pharm Co., Ltd. announced that it has received KRW 3.00003 billion in funding from GL Pharm Tech Corp.	18-05-22	CI
GL Pharm Tech Corp. announced that it has received KRW 7 billion in funding from Shinhan Investment Corp., Investment Arm, Samsung Securities Co. Ltd., Investment Arm, E&INVESTMENT INC. and other investors	18-05-13	CI
GL Pharm Tech Corp. announced that it expects to receive KRW 7 billion in funding from Shinhan Investment Corp., Investment Arm, Samsung Securities Co. Ltd., Investment Arm, E&INVESTMENT INC., and other investors	18-05-10	CI
GL Pharm Tech Corp. completed the acquisition of remaining 67.91% stake in Crown Pharm Co., Ltd.	18-01-25	CI
GL Pharm Tech Corp. agreed to acquire remaining 67.91% stake in Crown Pharm Co., Ltd. for KRW 3 billion.	18-01-23	CI
Crown Pharm Co., Ltd. announced that it has received KRW 5.499740208 billion in funding from GL Pharm Tech Corp.	18-01-23	CI
GL Pharm Tech Corp. announced that it has received KRW 2 billion in funding from Daone Chemical Co., Ltd., Genebiotech Co., Ltd.	18-01-16	CI
GL Pharm Tech Corp. agreed to acquire a 32.1% stake in Crown Pharmaceutical Co., Ltd. from Seungho Shin for KRW 1.4 billion.	17-11-14	CI

Chart GL Pharm Tech Corp.

Duration

Period

More charts

Company Profile

GL Pharm Tech Corp., formerly IBKS No.2 Special Purpose Acquisition Company, is a Korea-based company mainly engaged in the research and development of pharmaceutical products.

Sector

Biotechnology & Medical Research

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GL PHARM TECH CORP.	+3.08%	65.75M
MODERNA, INC.	+64.92%	62.86B
IQVIA HOLDINGS INC.	-1.85%	41.38B
LONZA GROUP AG	+44.76%	40.38B
CELLTRION, INC.	-8.93%	27.64B
ICON PUBLIC LIMITED COMPANY	+13.05%	26.46B
ALNYLAM PHARMACEUTICALS, INC.	-21.96%	18.9B
BIO-TECHNE CORPORATION	+4.21%	12.67B
UNITED THERAPEUTICS CORPORATION	+25.74%	12.27B
MEDPACE HOLDINGS, INC.	+27.42%	12.07B

Other Biotechnology & Medical Research